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Abstract
Purpose—Type 2 diabetes (T2D) has been reported to be associated with an elevated risk of 
breast cancer. It is unclear, however, whether this association is due to shared genetic factors.
Methods—We constructed a genetic risk score (GRS) using risk variants from 33 known 
independent T2D susceptibility loci and evaluated its relation to breast cancer risk using the data 
from two consortia, including 62,328 breast cancer patients and 83,817 controls of European 
ancestry. Unconditional logistic regression models were used to derive adjusted odds ratios (OR) 
and 95% confidence intervals (CI) to measure the association of breast cancer risk with T2D GRS 
or T2D-associated genetic risk variants. Meta-analyses were conducted to obtain summary ORs 
across all studies.
Results—The T2D GRS was not found to be associated with breast cancer risk, overall, by 
menopausal status, or for estrogen receptor positive or negative breast cancer. Three T2D 
associated risk variants were individually associated with breast cancer risk after adjustment for 
multiple comparisons using the Bonferroni method (at P < 0.001), rs9939609 (FTO) (OR = 0.94, 
95% CI = 0.92 – 0.95, P = 4.13E-13), rs7903146 (TCF7L2) (OR = 1.04, 95% CI = 1.02 – 1.06, P 
= 1.26E-05), and rs8042680 (PRC1) (OR = 0.97, 95% CI = 0.95 – 0.99, P = 8.05E-04).
Conclusions—We have shown that several genetic risk variants were associated with the risk of 
both T2D and breast cancer. However, overall genetic susceptibility to T2D may not be related to 
breast cancer risk.
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Introduction
Globally, approximately 382 million people currently live with diabetes, and this number 
may rise to 592 million by 2035 [1]. Type 2 diabetes (T2D), accounts for over 90% of all 
diabetes cases [2]. Breast cancer is the most common cancer among women in many 
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countries, including the United States [3]. Many epidemiological studies have linked T2D to 
increased breast cancer risk [4–8]. Recent meta-analyses have shown a more than 20% 
increase in risk of breast cancer among women with T2D compared to women without the 
disease [9–12]. T2D and breast cancer share some risk factors, including obesity in 
postmenopausal women and physical inactivity [13]. Elevated levels of circulating C-peptide 
and insulin-like growth factor-1, biomarkers related to insulin resistance, have also been 
associated with increased breast cancer risk [14,15]. It remains unclear, however, if the link 
between these two diseases is due to shared lifestyle risk factors or intrinsic etiology such as 
genetic susceptibility. Understanding how genetic variants related to T2D risk influence 
breast cancer risk may provide insights into the nature of the T2D-breast cancer relationship.
Recent genome-wide association studies (GWAS) have identified approximately 50 genetic 
variants associated with T2D risk. Some of these reported T2D-related genetic variants have 
been studied in relation to the risk of several cancers, including cancers of the pancreas [16], 
colon/rectum [17,18] and prostate [19]. The influence of these variants on breast cancer risk, 
however, has not been adequately studied. To date, only two studies have evaluated the 
association of a subset of these T2D-related genetic variants with breast cancer risk [20,21]. 
Both studies reported a null association, which may be due to small study size and low study 
power.
In this analysis, using data from two consortia including 62,328 breast cancer cases and 
83,817 controls of women of European ancestry, we evaluated T2D-related genetic variants 
reported to date in relation to breast cancer risk. By constructing a T2D-related genetic risk 
score (T2D GRS) and evaluating its association with breast cancer risk, we tested the 
hypothesis that, overall, the alleles that increase T2D risk may also increase breast cancer 
risk. We also tested the hypothesis that certain T2D-related genetic variants may be 
associated with breast cancer risk.
Methods
Study population
Included in this analysis were 62,328 breast cancer cases and 83,817 controls of women of 
European ancestry recruited either in the 39 studies (Online Resource Table 1) that 
participated in the Breast Cancer Association Consortium (BCAC), a part of the 
Collaborative Oncological Gene-Environment Study (COGS), or in the eleven studies 
(Online Resource Table 2) that are included in the Discovery, Biology, and Risk of Inherited 
Variants in Breast Cancer (DRIVE) project of Genetic Associations and Mechanism in 
Oncology (GAME-ON). From the BCAC, we included individual-level data for 46,325 
breast cancer cases and 42,482 controls. The DRIVE project included 16,003 breast cases 
and 41,335 controls; however, only summary statistics for the association between T2D-
related risk variants and breast cancer risk were available, and thus these summary statistics 
were used in our study. The study samples and participant data, including demographics and 
the traditional risk factors for breast cancer, were collected in each contributing study.
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Single nucleotide polymorphism (SNP) selection
We searched for all reported genetic risk variants associated with T2D in European ancestry 
populations at a genome-wide significance level (P < 5 × 10−8, trait “Type 2 diabetes” or 
“Type 2 diabetes and other traits”) using the US National Human Genome Resource Institute 
(NHGRI) Catalog of Published Genome-Wide Association Studies (GWAS Catalog, 
accessed November 19, 2012, at http://www.genome.gov/gwastudies). Fifty SNPs 
representing 33 independent loci (linkage disequilibrium (LD) R2 < 0.1) were identified 
(Fig. 1).
Genetic risk score construction
The genetic risk scores were calculated in 46,325 cases and 42,482 controls included in the 
BCAC. At each of the 33 independent loci, we selected the SNP with the lowest P-value for 
association with T2D reported in GWASs to represent the locus in constructing the T2D 
GRS. Using these 33 SNPs, a weighted T2D GRS was constructed as a measure of the 
overall association of genetic risk variants with T2D. In the BCAC, eleven SNPs were 
directly genotyped and 22 were imputed with imputation quality threshold of R2 > 0.5. The 
T2D GRS was created as , where wi is the logarithm of the odds ratio (OR) of 
the ith SNP with T2D reported from previous GWAS, and SNPi is the number of risk alleles 
carried by a given subject on the ith SNP. We hypothesized that the risk allele for T2D would 
be associated with increased risk of breast cancer. The 33 individual T2D risk variants 
identified from the NHGRI GWAS catalog are presented in Online Resource Table 3.
Genotyping
In the BCAC, genotype data were obtained either from direct genotyping with a custom 
Illumina iSelect genotyping array (iCOGS) that contains 211,155 SNPs [22] or from 
imputation with the 1000 Genomes Project Phase I integrated variant set (version 3, March 
2012 release) as the reference [23], using the program IMPUTE2 [24]. Details of the studies 
that participated in the BCAC, and the methodology used by the BCAC and iCOGS have 
been published elsewhere [22] and can also be found on the iCOGS website (http://
ccge.medschl.cam.ac.uk/research/consortia/icogs/).
In the DRIVE project, genotype data were obtained either from direct genotyping using 
Illumina or Affymetrix arrays (Online Resource Table 2) or from imputation with the 
HapMap version 2 CEU panel (Utah residents of Northern and Western European ancestry) 
as a reference, using the program MACH v1.0 or IMPUTE [24]. Details of the studies that 
participated in DRIVE were described in previously published papers [22,25–28] or on the 
GAME-ON website (http://gameon.dfci.harvard.edu).
Statistical analysis
We evaluated the association between the T2D GRS and breast cancer risk using individual-
level data from 46,325 breast cancer cases and 42,482 controls of European ancestry who 
participated in BCAC studies. Demographic characteristics and known breast cancer risk 
factors were summarized by case-control status using mean and standard deviation (SD) for 
continuous variables or frequency with percentage for categorical variables. Differences 
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between cases and controls were compared using the Wilcoxon rank sum test (continuous 
variables) or the χ2 test (categorical variables). To assess the association between the T2D 
GRS and breast cancer risk factors, we used control data and calculated the mean and SD of 
the T2D GRS by comparison groups for each categorical variable; the difference was tested 
by the Wilcoxon rank sum test. For continuous variables, the Pearson’s correlations were 
measured. To account for potential population stratification within our study population, 
genetic ancestry was estimated by principal component (PC) analysis using EIGENSTRAT 
software [29] on 37,000 uncorrelated SNPs (including those selected as ancestry informative 
markers) on the chip. The mean value of the genomic inflation factor (λ) was 1.01 for the 
participating studies when PCs were included in the regression models, indicating little 
evidence of population stratification [22]. For all analyses, the top eight PCs were included 
in all regression models. For the LMBC study, the study-specific principal component was 
further adjusted. To assess the association between the T2D GRS and breast cancer risk, we 
first fitted unconditional logistic regression models adjusting for age and PCs within each of 
the 39 contributing studies individually and recorded the β coefficients with standard errors 
for T2D GRS quintiles (relative to the first quintile). We then conducted a meta-analysis on 
the results from these 39 studies using both fixed effect and mixed effect models. The odds 
ratios (ORs) with 95% confidence intervals (CI) from the fixed effects model are reported in 
Table 1, as are further analyses by estrogen receptor (ER) status, menopausal status, age 
group (<50 vs. ≥50 years), and body mass index (BMI, <25 vs. ≥25 kg/m2).
We also used the SNP-set Kernel Association Test (SKAT) to evaluate whether any SNP in 
the T2D-associated SNP set may be related to breast cancer risk without making the 
assumption that the alleles that increase T2D risk may also increase breast cancer risk [30]. 
To evaluate the association of each individual SNP (per copy of risk allele) with breast 
cancer risk, we used individual-level data from the BCAC (46,325 cases and 42,482 
controls) and summary results data from DRIVE (16,003 cases and 41,335 controls). We 
first estimated allelic OR for each SNP for each BCAC study with adjustment similar to that 
in the analyses for the association of T2D GRS with breast cancer risk described above and 
then combined the results across all BCAC studies with results from DRIVE using the 
inverse-variance meta-analysis with a fixed-effect model. Both consortium-specific results 
and combined results are reported in Table 2. For individual SNP analyses, statistical 
significance was considered after adjusting for multiple comparisons using the Bonferroni 
method (0.05/33). For all other analyses, statistical significance was considered at a two-
sided 5% level unless stated otherwise. All analyses were conducted using R version 3.0.3 
[31].
Results
Among the 88,807 BCAC participants studied, on average, cases were slightly older than 
controls (57.8 vs. 54.9 years, P < 0.001) and entered menopause at a younger age (48.5 vs. 
48.7 years, P < 0.01), as shown in Online Resource Table 4. More cases than controls were 
postmenopausal (69.3% vs. 68.1%, P < 0.01) or had a first-degree family history of breast 
cancer (27.7% vs. 11.2%, P < 0.01). Among postmenopausal women, cases and controls had 
comparable BMI (P = 0.62). Among controls, the T2D GRS was positively correlated with 
BMI (postmenopausal women, Pearson r = 0.018, P = 0.03), and inversely correlated with 
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age at menarche (Pearson r = −0.021, P < 0.01). For other categorical variables examined, 
the mean T2D GRS values were virtually identical across different statuses (Online 
Resource Table 4, right columns).
Overall, the T2D GRS was not found to be associated with breast cancer risk (P for trend = 
0.69, Table 1). No significant results were observed in analyses stratified by ER status (P for 
trend = 0.74 and 0.47 for ER+ and ER− breast cancer, respectively), menopausal status (P 
for trend = 0.74 and 0.93 for premenopausal and postmenopausal women, respectively), age 
group (P for trend = 0.74 and 0.62 for age <50 and age ≥50 years, respectively), or BMI 
group (P for trend = 0.64 and 0.64 for BMI <25 and BMI ≥25, respectively). Meta-analysis 
using mixed effect models gave similar results (data not shown). In a sensitivity analysis, 
which included only the eleven directly genotyped SNPs and 14 imputed SNPs with 
imputation R2 > 0.9, similar results were observed (Online Resource Table 5).
Using SKAT tests and without making the assumption that the alleles that increase T2D risk 
also increase breast cancer risk, we found evidence for potential association for some of the 
T2D-related SNPs with breast cancer risk (P = 3.95E-10). Of the 33 independent SNPs 
investigated, seven were nominally associated with breast cancer risk using BCAC data 
alone (Table 2). Of these, the risk allele for T2D in four SNPs was associated with a reduced 
risk of breast cancer. After adjusting for multiple comparisons, the association for two SNPs, 
rs7903146 (TCF7L2, OR = 1.04, 95% CI = 1.02 – 1.07, P = 1.20E-04) and rs9939609 (FTO, 
OR = 0.93, 95% CI = 0.91 – 0.95, P = 3.63E-12), remained statistically significant, and both 
associations were replicated in DRIVE. SNP rs8042680 (PRC1) was related to breast cancer 
risk in the BCAC at P = 0.02 and in DRIVE at P = 6.18E-3; meta-analyses of these data 
yielded a significant association after adjusting for multiple comparisons (OR = 0.97, 95% 
CI = 0.99 – 0.99, P = 8.05E-4).
Discussion
In this large study, we investigated the association of 33 independent T2D related genetic 
variants with breast cancer risk individually and in combination (through the use of our 
GRS). Generally, we found no association between T2D GRS and risk of breast cancer 
overall or by ER status. Of the 33 T2D-associated SNPs investigated in this study, three 
showed a significant association with breast cancer risk after adjusting for multiple 
comparisons: rs9939609 (FTO), rs7903146 (TCF7L2), and rs8042680 (PRC1). Although 
this study does not provide any evidence for an overall association of T2D susceptibility and 
breast cancer risk, it does show that some T2D-associated SNPs may be related to breast 
cancer risk.
It has been hypothesized that the association between T2D and breast cancer may be 
mediated through insulin resistance and hyperinsulinaemia [32]. T2D and breast cancer 
share some lifestyle risk factors, including obesity in postmenopausal women and physical 
inactivity. Indeed, it has been shown previously that the observed association between these 
two diseases may be, in part, due to residual confounding by BMI [33]. With a very large 
sample size, our study suggests that overall genetic susceptibility to T2D was not related to 
breast cancer risk, indicating that the previously observed association between T2D and 
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breast cancer risk may be largely due to shared lifestyle risk factors. Our finding for a null 
association between T2D GRS and breast cancer risk is supported by two previous studies 
that investigated this association. In one of these studies, Chen et al. investigated 18 T2D-
related SNPs among 503 European ancestry cases and 633 controls from the multiethnic 
cohort and PAGE studies [20]. In the other study, Hou et al. pooled data for 25 genotyped 
and 15 imputed T2D-related SNPs from seven studies and investigated this association 
among 1,142 European ancestry cases and 1,137 European ancestry controls [21]. Neither 
study reported a significant association between T2D GRS and overall breast cancer risk. 
However, these two studies had evaluated a smaller set of T2D risk variants than the current 
study and the sample size in both studies was substantially smaller than the current study, 
and thus the statistical power in these two previous studies was low. For example, for a given 
SNP with a minor allele frequency of 0.3, the current study had 99.6% power to detect an 
OR of 1.05 at a type I error rate of 0.05, while, the previous studies had <15% power to 
detect an OR of 1.05.
We identified three T2D risk variants that were associated with breast cancer risk. SNPs in 
strong correlation with each of these three variants have recently been identified in GWAS to 
be associated with breast cancer risk. SNP rs9939609 (FTO) located in region 16q12.2, and 
rs7903146 (TCF7L2) located in region 10q25.2 are in perfect LD (R2 = 1) with rs17817449 
and rs7904519, respectively, which were identified in relation to breast cancer risk in a 
GWAS conducted using BCAC data [22]. SNP rs8042680 (PRC1) is in strong LD with 
rs2290203 (R2 = 0.59, 9,270bp apart) that was recently identified as a risk variant for breast 
cancer in a GWAS conducted in East Asian women [34]. Interestingly, the T2D-risk allele of 
rs9939609 and rs8042680 are associated with a decreased risk of breast cancer. Though 
studies have suggested that TCF7L2 may associate with breast cancer through the wnt/β-
catenin pathway [35,36], the exact mechanisms underlying these associations are unclear. 
Further studying these genes may uncover additional insights into the biology and genetics 
that link the risk of breast cancer and T2D.
The sample size for our study was very large. When comparing subjects in T2D GRS Q5 to 
those in Q1, our study had 80% power to detect an OR for breast cancer risk as low as 1.06 
(or 0.94) at 5% type I error rate. Our study showed that the association between T2D GRS 
and breast cancer risk should be very small, if it exists. The GRS used in our study was 
constructed using SNPs with established association with T2D, as demonstrated 
convincingly in previous GWAS, and thus this GRS should have a clear association with 
T2D. Indeed, using the resources from the Nashville Breast Health Study [37], we showed 
that this GRS was related to T2D in a dose-response manner (P for trend < 0.01, Online 
Resource Table 6). However, there are some potential limitations of our study. The T2D 
treatment information was not available for the study, preventing us from conducting an in-
depth evaluation of the potential influence of T2D treatment on the association of T2D risk 
variants with breast cancer risk. To reduce potential influence of T2D treatment, we 
conducted an analysis among younger patients (< 50 years old) who are less likely to have 
T2D diagnosis than the older age group. This analysis showed similar results in younger and 
older groups (Table 2), indicating that the influence of T2D treatment on the association of 
T2D risk variants with breast cancer risk should be small. Approximately two-thirds of the 
SNPs used to construct the T2D GRS were not directly genotyped. We imputed these SNPs 
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using 1000 Genomes Project data as the reference. The imputation quality was high. In a 
sensitivity analysis, we constructed an alternate T2D GRS using only the 11 directly 
genotyped SNPs and the 14 imputed SNPs which had almost perfect quality (R2 > 0.9). This 
T2D GRS is highly correlated with the T2D GRS used in our primary analysis (Pearson’s r 
= 0.93) and using the alternate T2D GRS did not change the results appreciably. Since we 
started this project, 14 new genetic loci for T2D have been identified. Unfortunately, we 
don’t have any data for these 14 new loci for our study. However, the strength of the 
association of T2D risk is much weaker for these newly identified variants than the 33 
variants identified previously and included in our study. Therefore, we believe that including 
these variants would not change the conclusion of this study. Finally, all participants in this 
study are of European ancestry, possibility affecting the generalizability of our study 
findings to other populations.
In conclusion, our study found no apparent association between a polygenetic score 
constructed using the known T2D risk variants identified to date in GWAS and breast cancer 
risk among women of European ancestry. It is possible that the previously reported 
association between these two diseases could be due to shared lifestyle risk factors for T2D 
and breast cancer, providing support for lifestyle modification as an effective prevention 
strategy to reduce the risk of both T2D and breast cancer. Our finding of significant 
associations of three T2D risk variants with breast cancer suggests a potential link of certain 
shared genetic and biological pathways for these common diseases.
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Fig. 1. 
Overview of the T2D genetic risk score construction
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